Skip to main content

Global Selector
Newsroom
Partnering
Contact

We Are CSL

We Are CSL

Our Businesses and Products

Vita: Original Stories

Our Leadership

Worldwide Locations

Corporate Governance

Our Businesses and Products

CSL Behring

CSL Seqirus

CSL Vifor

Corporate Governance

Code of Responsible Business Practice

Core Policies

Vita means life. It's also our platform for sharing the stories of biotech's promise to patients and public health.
Read the Stories

CSL consists of CSL Behring, CSL Seqirus and CSL Vifor. Learn more by visiting each section.
Our Businesses and Products
Patients & Public Health

Patients & Public Health

Rare & Serious Diseases

Iron Deficiency

Nephrology

Vaccines

Patient Support & Organizations

Rare & Serious Diseases

Immunodeficiency and Autoimmune Diseases

Hereditary Bleeding Disorders

Hereditary Angioedema

Alpha 1 Antitrypsin Deficiency

Iron Deficiency

Iron Deficiency Patient Stories

Nephrology

Nephrology Patient Stories

Vaccines

COVID-19

Pandemic Response

In-Licensing

Antivenoms and Q fever Vaccine

Patient Support & Organizations

CSL Behring USA Support & Assistance Programs

CSL Vifor Managed Access Programs

LEAD Grants

Biotechnology leader CSL Behring offers the broadest range of quality plasma-derived and recombinant therapies in our industry.
CSL Behring: Rare & Serious Diseases

Derived from the expression 'securing health for all of us', CSL Seqirus is one of the world's largest influenza vaccine providers.
CSL Seqirus: Vaccines
R&D

R&D

R&D Capabilities

Awards, Grants and Initiatives

World-Class R&D Network

Product Pipeline

Clinical Studies at CSL

Clinical Studies at CSL

Current Clinical Trials

Research Practices

How to Participate

Clinical Studies FAQs

R&D focuses its expertise on four strategic platforms: plasma protein technology; recombinant technology; cell and gene therapy; and vaccines technology.
R&D Capabilities

One of our core values at CSL is Innovation. We support collaborative innovation through the endowment of awards and grants to researchers around the world.
Awards, Grants and Initiatives
Sustainability

Sustainability

Healthier Environment

Healthier Communities

Promising Futures

Governance

Data and Reporting Centre

Healthier Environment

Climate Resilience

Energy

Water and Waste

Healthier Communities

Product Safety & Quality

Innovation and R&D

Access and Affordability

Responsible & Resilient Supply Chain

Donor Experience

Patient Experience

Promising Futures

Talent and Culture

Health, Safety & Wellbeing

Inclusion and Belonging

Governance

Ethics & Transparency

Data Protection & Privacy

Stakeholder Engagement & Material Topics

Data and Reporting Centre

Annual Publications

Policies

Key Performance Data Summary

As part of our broader sustainability strategy to build a more sustainable future, we've committed to a 40% reduction in absolute Scope 1 and 2 emissions by 2030.
Learn About Our Targets

Along with our sustainability strategy, CSL’s community contribution framework helps deliver on our Values and support execution of our 2030 strategy.
Supporting Our Communities
Careers

Careers

Diversity, Equity & Inclusion

How CSL Supports Your Well-being

Early Careers at CSL

Early Careers at CSL

Apprenticeships

Internships at CSL

Graduate Rotational Programs at CSL

At CSL, Diversity, Equity, and Inclusion (DEI) is at the core of our mission and who we are. It fuels our innovation day in and day out.
Read About Our DE&I

Whether you are early in your college education or recently completed your degree, it's never too soon to consider CSL for your Promising Future!
Early Careers at CSL
Investors

Search

We Are CSL
- Our Businesses and Products
- Corporate Governance
Patients & Public Health
- Rare & Serious Diseases
- Iron Deficiency
- Nephrology
- Vaccines
- Patient Support & Organizations
R&D
- Clinical Studies at CSL
Sustainability
- Healthier Environment
- Healthier Communities
- Promising Futures
- Governance
- Data and Reporting Centre
Careers
- Early Careers at CSL
Global Selector

CSL
We Are CSL
Vita: Original Stories
Should You Be Tested for Alpha-1?

Should You Be Tested for Alpha-1?

Experts encourage testing folks diagnosed with COPD, emphysema or chronic bronchitis.

By Jim Senft 30 Mar 2018

Story

Topics

Alpha 1 Antitrypsin Deficiency Diagnosis Video

Related

share

Terms of Use Cookie Policy Global Privacy Policy Accessibility Statement Sitemap

Terms of Use
Cookie Policy
Global Privacy Policy
Accessibility Statement
Sitemap

CSL, All Rights Reserved © 2025

Search

CSL

CSL (CSL Behring's Parent Company)

CSL Behring Worldwide

Americas

Argentina
Brazil
Canada
Chile
Colombia
Mexico

Asia Pacific

Australia
China
Japan
Korea
Singapore
Taiwan

Middle East

Saudi Arabia
United Arab Emirates (MEA)

Europe

Austria
Belgium and Luxembourg
Czech Republic
Denmark
Finland
France
Germany
Greece
Hungary
Iceland
Italy
Netherlands
Norway
Poland
Slovakia
Spain
Sweden
Switzerland
Turkey
United Kingdom

CSL Plasma (CSL Behring Subsidiary)

CSL Plasma US
CSL Plasma Germany
CSL Plasma Hungary